Ernexa Therapeutics Statistics Share Statistics Ernexa Therapeutics has 7.66M
shares outstanding. The number of shares has increased by 0.03%
in one year.
Shares Outstanding 7.66M Shares Change (YoY) 0.03% Shares Change (QoQ) 1.7% Owned by Institutions (%) 2.79% Shares Floating 3.38M Failed to Deliver (FTD) Shares 139 FTD / Avg. Volume 0.16%
Short Selling Information The latest short interest is 49.47K, so 0.67% of the outstanding
shares have been sold short.
Short Interest 49.47K Short % of Shares Out 0.67% Short % of Float 0.83% Short Ratio (days to cover) 1.57
Valuation Ratios The PE ratio is -2.81 and the forward
PE ratio is -0.01.
Ernexa Therapeutics's PEG ratio is
0.05.
PE Ratio -2.81 Forward PE -0.01 PS Ratio 215.18 Forward PS 0.1 PB Ratio 73.62 P/FCF Ratio -7.73 PEG Ratio 0.05
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Ernexa Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.8,
with a Debt / Equity ratio of 0.4.
Current Ratio 0.8 Quick Ratio 0.8 Debt / Equity 0.4 Debt / EBITDA -0.02 Debt / FCF -0.04 Interest Coverage -2.32
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $97K Profits Per Employee $-7.42M Employee Count 6 Asset Turnover 0.11 Inventory Turnover n/a
Taxes Income Tax 30K Effective Tax Rate -0.07%
Stock Price Statistics The stock price has increased by -94.58% in the
last 52 weeks. The beta is 6.74, so Ernexa Therapeutics's
price volatility has been higher than the market average.
Beta 6.74 52-Week Price Change -94.58% 50-Day Moving Average 1.71 200-Day Moving Average 3.62 Relative Strength Index (RSI) 29.56 Average Volume (20 Days) 84,845
Income Statement In the last 12 months, Ernexa Therapeutics had revenue of 582K
and earned -44.54M
in profits. Earnings per share was -1.57.
Revenue 582K Gross Profit 486K Operating Income -15.67M Net Income -44.54M EBITDA -36.12M EBIT -37.76M Earnings Per Share (EPS) -1.57
Full Income Statement Balance Sheet The company has 1.73M in cash and 684K in
debt, giving a net cash position of 1.04M.
Cash & Cash Equivalents 1.73M Total Debt 684K Net Cash 1.04M Retained Earnings -231.54M Total Assets 7.58M Working Capital 2.14M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -15.84M
and capital expenditures -369K, giving a free cash flow of -16.2M.
Operating Cash Flow -15.84M Capital Expenditures -369K Free Cash Flow -16.2M FCF Per Share -0.57
Full Cash Flow Statement Margins Gross margin is 83.51%, with operating and profit margins of -2693.13% and -7652.75%.
Gross Margin 83.51% Operating Margin -2693.13% Pretax Margin -7647.59% Profit Margin -7652.75% EBITDA Margin -6206.01% EBIT Margin -2693.13% FCF Margin -2784.36%
Dividends & Yields ERNA does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for ERNA.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 12, 2025. It was a
backward
split with a ratio of 1:15.
Last Split Date Jun 12, 2025 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -56.67 Piotroski F-Score 6
